References
- Olivieri I, D'Angelo S, Palazzi C, et al. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10:531–542.
- D'Angelo S, Tramontano G, Gilio M, et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. OARRR. 2017;9:21–28.
- Tan WS, Kelly S, Pitzalis C. Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2017;13:207–222.
- Brezinski EA, Armstrong AW. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis. CMC. 2015;22:1930–1942.
- Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339.
- Shirley M, Scott LJ. Secukinumab: a review in psoriatic arthritis. Drugs. 2016;76:1135–1145.
- McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.